NCT07050940View on ClinicalTrials.gov

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study

NARecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions
Melanoma Metastatic
Interventions
DIETARY_SUPPLEMENT

Postbiotic

postbiotic food supplement PostbiotiX-HLA 1 capsule (200mg) /day

DRUG

AntiPD1

Antibody to PD1 approved for standard of care

Trial Locations (5)

Unknown

NOT_YET_RECRUITING

Bari University-Oncologia medica, Bari

NOT_YET_RECRUITING

Torino University-Le Molinette, Torino

NOT_YET_RECRUITING

IRCCS Papa Giovanni II Bari, Bari

NOT_YET_RECRUITING

INT Milano, Milan

06132

RECRUITING

AO Perugia, Perugia

All Listed Sponsors
collaborator

Istituto Clinico Humanitas

OTHER

lead

Azienda Ospedaliera di Perugia

OTHER